EGRX - Eagle Pharmaceuticals Inc
IEX Last Trade
5.13
-0.110 -2.144%
Share volume: 53,661
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.24
-0.11
-2.10%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
| Report Date | 2022-05-09 | 2022-08-09 | 2022-11-09 | 2023-03-23 | 2023-05-09 | 2023-08-08 | |
| Assets | |||||||
| Total Assets | 320.165 M | 381.756 M | 386.449 M | 406.160 M | 414.175 M | 404.822 M | |
| Current Assets | 240.166 M | 194.456 M | 185.046 M | 188.754 M | 192.491 M | 187.250 M | |
| Inventories | 24.818 M | 57.712 M | 63.855 M | 47.794 M | 44.140 M | 42.482 M | |
| Other Current Assets | 14.968 M | 14.262 M | 8.875 M | 13.200 M | 11.501 M | 14.274 M | |
| Short Term Investments | 14.968 M | 14.262 M | 8.875 M | 13.200 M | 11.501 M | 14.274 M | |
| Total Receivables | 130.858 M | 85.920 M | 96.932 M | 72.439 M | 114.953 M | 115.140 M | |
| Current Cash | 69.522 M | 36.562 M | 15.384 M | 55.321 M | 21.897 M | 15.354 M | |
| Total Non-current Assets | 79.999 M | 187.300 M | 201.403 M | 217.406 M | 221.684 M | 217.572 M | |
| Property Plant Equipment | 1.627 M | 1.459 M | 1.297 M | 1.168 M | 1.116 M | 1.013 M | |
| Other Assets | 7.458 M | 7.066 M | 25.986 M | 25.732 M | 33.510 M | 33.405 M | |
| Intangible Assets | 9.940 M | 112.474 M | 108.785 M | 118.327 M | 112.875 M | 107.406 M | |
| Goodwill | 39.743 M | 43.057 M | 41.794 M | 45.033 M | 45.033 M | 45.033 M | |
| Liabilities and shareholders’ equity | |||||||
| Total Liabilities and shareholders’ equity | 320.165 M | 381.756 M | 386.449 M | 406.160 M | 414.175 M | 404.822 M | |
| Total liabilities | 104.205 M | 143.774 M | 154.669 M | 172.600 M | 171.330 M | 152.782 M | |
| Total current liabilities | 101.642 M | 108.964 M | 121.828 M | 111.087 M | 97.809 M | 86.630 M | |
| Accounts Payable | 14.509 M | 19.971 M | 13.215 M | 18.993 M | 17.108 M | 15.843 M | |
| Other liabilities | 2.563 M | 2.256 M | 1.874 M | 5.297 M | 4.692 M | 4.256 M | |
| Current long term debt | 23.725 M | 21.843 M | 34.961 M | 6.250 M | 7.500 M | 8.297 M | |
| Long term debt | 0.000 | 28.018 M | 26.431 M | 56.216 M | 68.829 M | 61.896 M | |
| Other liabilities | 2.563 M | 2.256 M | 1.874 M | 5.297 M | 4.692 M | 4.256 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 215.960 M | 237.982 M | 231.780 M | 233.560 M | 242.845 M | 252.040 M | |
| Common stock | 12.711 M | 12.836 M | 13.167 M | 13.022 M | 13.059 M | 13.091 M | |
| Retained earnings | 119.920 M | 110.470 M | 103.339 M | 111.504 M | 117.254 M | 122.418 M |